Panelists report that the AUGMENT-101 trial demonstrated meaningful clinical benefits of menin inhibitors in relapsed/refractory KMT2A-rearranged acute myeloid leukemia (AML)—with a 23% complete ...
KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no ...
Acute promyelocytic leukaemia (APL) represents a unique and once highly fatal subtype of acute myeloid leukaemia that is now considered among the most curable forms of haematological malignancies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results